What is Zacks Research’s Estimate for COO Q1 Earnings?

The Cooper Companies, Inc. (NASDAQ:COO) – Zacks Research raised their Q1 2026 earnings estimates for Cooper Companies in a research note issued on Wednesday, December 24th. Zacks Research analyst Team now anticipates that the medical device company will post earnings per share of $1.02 for the quarter, up from their prior forecast of $1.01. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q2 2026 earnings at $1.07 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $4.45 EPS, Q1 2027 earnings at $1.15 EPS, Q2 2027 earnings at $1.17 EPS, Q3 2027 earnings at $1.24 EPS, Q4 2027 earnings at $1.28 EPS, FY2027 earnings at $4.84 EPS and FY2028 earnings at $5.33 EPS.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the business posted $1.04 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS.

A number of other equities analysts also recently issued reports on COO. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Barclays reaffirmed an “overweight” rating and issued a $91.00 target price on shares of Cooper Companies in a report on Monday, December 8th. Robert W. Baird lifted their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. JPMorgan Chase & Co. upped their price target on Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, December 5th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $71.00 price objective (up from $64.00) on shares of Cooper Companies in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus target price of $90.15.

Cooper Companies Price Performance

Cooper Companies stock opened at $82.32 on Thursday. The company has a market cap of $16.13 billion, a P/E ratio of 43.79, a price-to-earnings-growth ratio of 2.36 and a beta of 1.05. Cooper Companies has a one year low of $61.78 and a one year high of $100.24. The business has a fifty day moving average of $75.49 and a two-hundred day moving average of $72.30. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89.

Cooper Companies announced that its board has initiated a share buyback plan on Wednesday, September 17th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Cooper Companies

In related news, Director Cynthia L. Lucchese bought 1,784 shares of the stock in a transaction on Monday, December 22nd. The shares were purchased at an average price of $84.06 per share, for a total transaction of $149,963.04. Following the acquisition, the director owned 9,445 shares in the company, valued at $793,946.70. This represents a 23.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Maria Rivas purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $82.13 per share, with a total value of $82,130.00. Following the completion of the acquisition, the director owned 11,141 shares of the company’s stock, valued at approximately $915,010.33. The trade was a 9.86% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 18,014 shares of company stock worth $1,441,196 in the last quarter. Insiders own 1.98% of the company’s stock.

Institutional Trading of Cooper Companies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bell Investment Advisors Inc boosted its position in shares of Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after acquiring an additional 219 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of Cooper Companies during the 1st quarter valued at $40,000. J.Safra Asset Management Corp increased its holdings in shares of Cooper Companies by 204.8% during the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares during the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Cooper Companies in the 2nd quarter worth $36,000. Finally, MUFG Securities EMEA plc acquired a new position in Cooper Companies in the second quarter valued at $42,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Experienced board addition — CooperCompanies appointed Walter M. Rosebrough Jr., former STERIS CEO, as an independent director effective Jan. 3, 2026. His track record in medical devices and the Board’s pledge to consider him for Chair by end‑2026 are being viewed as a credibility and governance upgrade that could support strategic execution. CooperCompanies Appoints Walter M Rosebrough, Jr to its Board of Directors
• Positive Sentiment: Insider buying — Director Cynthia L. Lucchese bought 1,784 shares at ~$84.06 on Dec. 22, increasing her stake ~23%. Recent insider purchases are often read as confidence signals and can support sentiment while the market evaluates governance changes. SEC Filing — Insider Purchase
• Neutral Sentiment: Cooperation agreement and filings — The Company entered a cooperation agreement with Browning West, which includes standstill/voting commitments and an 8‑K disclosure. These formalize the arrangement but don’t immediately change fundamentals; investors should read the filed agreement for specifics on governance and timing. Press Release / 8‑K Disclosure
• Neutral Sentiment: Short‑interest data appears unreliable — a December entry shows “0 shares” and NaN changes; treat that as a data anomaly rather than a market signal until exchanges/feeds correct the figure.
• Negative Sentiment: Activist/uncertainty risk — Browning West’s involvement signals prior shareholder dissatisfaction. While cooperative now, the process of board refresh, potential shifts in capital allocation or strategic priorities, and transition risk can create short‑term volatility until execution clarity arrives. Quiver Quant — Cooperation Agreement Summary

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.